Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

The ERA Chair for Translational Genomics and Personalized Medicine

Descripción del proyecto

Investigación genómica traslacional innovadora en la Universidad de Tartu

La genómica traslacional desempeña un papel vital para ampliar los conocimientos sobre la biología humana y facilitar el descubrimiento de nuevos tratamientos y estrategias de prevención de enfermedades. En el proyecto TransGeno, financiado con fondos europeos, se pretende establecer el Centro de Genómica Traslacional como unidad permanente y sostenible en la Universidad de Tartu (UT). Para el proyecto se contratará a un distinguido investigador como director de la cátedra del Espacio Europeo de Investigación (EEI) de Genómica Traslacional en la UT. El objetivo principal del director de cátedra del EEI será reunir un equipo altamente cualificado dedicado a realizar investigaciones genómicas traslacionales innovadoras. Su labor será desarrollar y aplicar el primer plan de estudios de doctorado sobre Genómica Traslacional en Europa Oriental. El director de cátedra del EEI colaborará con otros departamentos de la UT, fomentando asociaciones con instituciones punteras de todo el mundo.

Objetivo

TransGeno seeks to hire a top researcher as ERA Chair of Translational Genomics at the University of Tartu (UT). In addition to assembling a highly skilled team to engage in cutting edge translational genomic research, the ERA Chair will promote change throughout the university in several ways:

• Establishing the Centre of Translational Genomics as a permanent and sustainable unit within UT
• Implementing a PhD curriculum on Translational Genomics - the first one of its kind in Eastern Europe.
• Coordinate with other departments to make more efficient and effective use of UT’s research capacity.
• Forge partnerships with leading institutions to attract top students and researchers from around the world as well as additional funding.

The ERA Chair will also engage with various stakeholders, including:

• Health sector business clusters to explore ways to exploit research results
• Medical doctors to educate them on how one form of TG information, clinical genomic data, can be useful in everyday practice.
• Youth and the general public to popularize genomics and spur young people into STEM sciences.
• International researchers by sharing research data and results in as open way as possible, either at ‘green’ or ‘gold’ open access standards.

TG applies innovations from genomics to diagnostics, prognostics and therapies for cancer, neurological disorders, diabetes and other complex diseases. It enables scientists to understand the genetic components of disease, which could lead to a shift from treatment based on symptoms to treatment based on underlying causes of disease. As Europe’s population ages and people must live with chronic diseases for longer this becomes more important. Advances in TG research could lead to early treatment of diseases and in the most ideal scenarios, enable doctors to treat patients before the onset of disease. TransGeno will increase research excellence in Estonia and enable UT to become a world leader in these efforts.

Convocatoria de propuestas

H2020-WIDESPREAD-2014-2015

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-WIDESPREAD-2014-2

Régimen de financiación

CSA - Coordination and support action

Coordinador

TARTU ULIKOOL
Aportación neta de la UEn
€ 2 409 700,00
Dirección
ULIKOOLI 18
51005 Tartu
Estonia

Ver en el mapa

Región
Eesti Eesti Lõuna-Eesti
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
€ 2 677 500,00